Brian Budke to Rad51 Recombinase
This is a "connection" page, showing publications Brian Budke has written about Rad51 Recombinase.
Connection Strength
2.943
-
Optimization of Drug Candidates That Inhibit the D-Loop Activity of RAD51. ChemMedChem. 2019 05 17; 14(10):1031-1040.
Score: 0.628
-
Recent Developments Using Small Molecules to Target RAD51: How to Best Modulate RAD51 for Anticancer Therapy? ChemMedChem. 2016 11 21; 11(22):2468-2473.
Score: 0.529
-
Real-time solution measurement of RAD51- and RecA-mediated strand assimilation without background annealing. Nucleic Acids Res. 2013 Jul; 41(13):e130.
Score: 0.416
-
An optimized RAD51 inhibitor that disrupts homologous recombination without requiring Michael acceptor reactivity. J Med Chem. 2013 Jan 10; 56(1):254-63.
Score: 0.406
-
RI-1: a chemical inhibitor of RAD51 that disrupts homologous recombination in human cells. Nucleic Acids Res. 2012 Aug; 40(15):7347-57.
Score: 0.388
-
Development of Small Molecules that Specifically Inhibit the D-loop Activity of RAD51. J Med Chem. 2016 05 26; 59(10):4511-25.
Score: 0.128
-
Dual and Opposite Effects of hRAD51 Chemical Modulation on HIV-1 Integration. Chem Biol. 2015 Jun 18; 22(6):712-23.
Score: 0.120
-
RAD54 family translocases counter genotoxic effects of RAD51 in human tumor cells. Nucleic Acids Res. 2015 Mar 31; 43(6):3180-96.
Score: 0.118
-
The RAD51-stimulatory compound RS-1 can exploit the RAD51 overexpression that exists in cancer cells and tumors. Cancer Res. 2014 Jul 01; 74(13):3546-55.
Score: 0.111
-
Rad51 is an accessory factor for Dmc1-mediated joint molecule formation during meiosis. Science. 2012 Sep 07; 337(6099):1222-5.
Score: 0.099